National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 5 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Clade C ALVAC and gp120 HIV VaccineCompletedNCT03284710Phase 1/2Results posted
• YCFM (Youth Correctional Facilities Males)CompletedNCT03249935Phase 2Results posted
• Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative AdultsCompletedNCT03239483Phase 1Results posted
• Polyclonal Regulatory T Cells (PolyTregs) for PemphigusTerminatedNCT03239470Phase 1Results posted
• Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03227029Phase 1Results posted
• Brentuximab Vedotin for Systemic SclerosisCompletedNCT03222492Phase 1/2Results posted
• Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected AdultsCompletedNCT03220724Phase 1Results posted
• Treatment of Gardnerella Vaginalis Vaginal Colonization With AmoxicillinCompletedNCT03211156Phase 2Results posted
• Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral TherapyCompletedNCT03208231Phase 1/2Results posted
• Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy AdultsCompletedNCT03186781Phase 1Results posted
• Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNACompletedNCT03181789Phase 1Results posted
• Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenActive, not recruitingNCT03164564Phase 3Results posted
• Targeted Microbiome Transplant in Atopic DermatitisCompletedNCT03151148Phase 1/2Results posted
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIVCompletedNCT03141060Phase 1/2Results posted
• Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult ParticipantsCompletedNCT03122223Phase 1/2Results posted
• VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and AdolescentsCompletedNCT03110770Phase 2Results posted
• Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT03102034Phase 1Results posted
• JBT-101 in Systemic Lupus Erythematosus (SLE)CompletedNCT03093402Phase 2Results posted
• Dose Escalation PfSPZ-CVacCompletedNCT03083847Phase 1Results posted
• Two Doses of Multimeric-001 (M-001) Followed by Influenza VaccineCompletedNCT03058692Phase 2Results posted
• Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide VaccineCompletedNCT03055000Phase 1Results posted
• Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy AdultsCompletedNCT03049488Phase 1Results posted
• Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their InfantsCompletedNCT03048422Phase 3Results posted
• Multiple Ascending Dose Study of Oxfendazole in Healthy Adult VolunteersCompletedNCT03035760Phase 1Results posted
• VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT03015181Phase 1Results posted
• Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic AreaCompletedNCT03008122Phase 1Results posted
• Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE SyndromeTerminatedNCT02996448Phase 2Results posted
• Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South AfricaCompletedNCT02968849Phase 2/3Results posted
• Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria GonorrhoeaeCompletedNCT02961751Not applicableResults posted
• Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in MaliCompletedNCT02942277Phase 1Results posted
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 2Results posted
• Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected AdultsCompletedNCT02915016Phase 1/2Results posted
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIVCompletedNCT02906007Phase 1/2Results posted
• Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in ChildrenCompletedNCT02891915Phase 4Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of AgeTerminatedNCT02890381Phase 1Results posted
• Partnership for Research on Ebola VACcinationsCompletedNCT02876328Phase 2Results posted
• Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205CompletedNCT02852005Phase 1Results posted
• Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic AdultsCompletedNCT02840474Phase 1Results posted
• Using Biomarkers to Predict TB Treatment DurationCompletedNCT02821832Phase 2Results posted
• GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in SemenCompletedNCT02818582Phase 2Results posted
• Genomic Responses of Human Immune and Non-Immune Cells to GlucocorticoidsCompletedNCT02798523Phase 1Results posted
• Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected AdultsCompletedNCT02797171Phase 1Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of AgeCompletedNCT02794870Phase 1Results posted
• Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy AdultsCompletedNCT02788188Phase 1Results posted
• Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment InterruptionCompletedNCT02788175Phase 1Results posted
• Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 InfectionCompletedNCT02778204Phase 1Results posted
• LACTIN-V Study for Recurrent Bacterial VaginosisCompletedNCT02766023Phase 2Results posted
• A Cohort Study of Operationally Tolerant Allograft RecipientsTerminatedNCT02743793Results posted
• Impact of CCR5 Blockade in HIV+ Kidney Transplant RecipientsCompletedNCT02741323Phase 2Results posted
• Auranofin for Giardia ProtozoaCompletedNCT02736968Phase 2Results posted
• Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenCompletedNCT02720094Phase 2/3Results posted
• Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With MenCompletedNCT02716675Phase 2Results posted
• Treg Therapy in Subclinical Inflammation in Kidney TransplantationCompletedNCT02711826Phase 1/2Results posted
• Cockroach Nasal Allergen Challenge PilotCompletedNCT02710136Phase 1Results posted
• Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial VaginosisCompletedNCT02709005Phase 2Results posted
• Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, BangladeshCompletedNCT02678455Phase 2Results posted
• Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV InfectionCompletedNCT02664415Phase 2Results posted
• Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)TerminatedNCT02663674Phase 4Results posted
• Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum WomenCompletedNCT02651259Phase 1/2Results posted
• Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa LoaTerminatedNCT02644525Phase 2Results posted
• Cardiometabolic Effects of Eplerenone in HIV InfectionTerminatedNCT02629094Phase 2Results posted
• Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid ArthritisTerminatedNCT02603146Phase 2Results posted
• Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV InfectionCompletedNCT02591420Phase 1Results posted
• Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary TuberculosisCompletedNCT02583048Phase 2Results posted
• Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza ACompletedNCT02572817Phase 3Results posted
• Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in WomenCompletedNCT02568215Phase 2Results posted
• Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy AdultsCompletedNCT02562482Phase 2Results posted
• Emtricitabine/Tenofovir Alafenamide as Salvage ARTTerminatedNCT02556333Phase 2Results posted
• Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver TransplantationCompletedNCT02533180Phase 2Results posted
• Subcutaneous Immunotherapy for Mouse in AdultsCompletedNCT02532179Phase 1/2Results posted
• Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)CompletedNCT02519777Phase 4Results posted
• Magnesium Supplementation in People With XMEN SyndromeCompletedNCT02496676Phase 1/2Results posted
• Effects of Inhibiting Early Inflammation in Kidney Transplant PatientsCompletedNCT02495077Phase 2Results posted
• Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza VaccinationTerminatedNCT02485639Phase 4Results posted
• Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected AdultsCompletedNCT02475655Phase 2Results posted
• Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) ReductionCompletedNCT02474199Phase 1/2Results posted
• VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment InterruptionCompletedNCT02471326Phase 1Results posted
• Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment InterruptionCompletedNCT02463227Phase 1Results posted
• Xenodiagnosis After Antibiotic Treatment for Lyme DiseaseCompletedNCT02446626Not applicableResults posted
• Autologous Polyclonal Tregs for LupusTerminatedNCT02428309Phase 1Results posted
• Pretomanid in Adults With Hepatic ImpairmentTerminatedNCT02422524Phase 1Results posted
• Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)CompletedNCT02411539Phase 1Results posted
• A Safety and Immune Response Study of 2 Experimental HIV VaccinesCompletedNCT02404311Phase 1/2Results posted
• Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy VolunteersTerminatedNCT02385123Phase 4Results posted
• Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge ModelCompletedNCT02371668Phase 2Results posted
• Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola InfectionCompletedNCT02363322Phase 1/2Results posted
• Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)CompletedNCT02344407Phase 2Results posted
• Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected AdultsCompletedNCT02344290Phase 3Results posted
• Tocilizumab (TCZ) in New-onset Type 1 DiabetesCompletedNCT02293837Phase 2Results posted
• Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With InfluenzaCompletedNCT02287467Phase 3Results posted
• Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant CyclophosphamideTerminatedNCT02282904Phase 1/2Results posted
• B Cell Induction in Pediatric Lung TransplantationCompletedNCT02266888Phase 2Results posted
• Rituximab and Belimumab for Lupus NephritisCompletedNCT02260934Phase 2Results posted
• Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of GonorrheaCompletedNCT02257918Phase 2Results posted
• Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsCompletedNCT02256631Phase 1Results posted
• Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat AllergyCompletedNCT02237196Phase 1/2Results posted
• Phase I Trial Evaluating the Safety and Pharmacokinetics of OxfendazoleCompletedNCT02234570Phase 1Results posted
• Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeCompletedNCT02231879Phase 2/3Results posted
• Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in AdolescentsCompletedNCT02213328Phase 2Results posted
• Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT02199496Phase 1/2Results posted

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas